The move would add another barrier for parents who want to vaccinate healthy children ahead of the respiratory virus season.

Novavax ( ($NVAX) ) has risen by 19.30%. Read on to learn why. Novavax has seen a remarkable 19.30% increase in its stock price over the past ...

“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

Drastic changes are brewing at the FDA, as newly appointed Commissioner Dr. Marty Makary indicates a shift toward stricter scientific accountability in vaccine approvals. In a notable departure from ...

The U.S. Food and Drug Administration may not renew its authorization for Pfizer's COVID-19 vaccine approved for children ...

Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Discover Novavax's Q2 2025 earnings insights: raised revenue targets, cost reductions, key partnerships with Sanofi & Takeda, and progress in ...

Two other covid vaccines expected to be available this fall, Novavax’s Nuvaxovid and Moderna’s mNexspike, are also restricted. They are approved for people 65 or older and those 12 to 64 who have ...

AMA and other medical associations are kicked out of CDC vaccine workgroups Experts are being disinvited from the workgroups that have been the backbone of the Advisory Committee on Immunization ...

Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna reported disappointing Q2 results.

FDA vaccine chief Dr. Vinay Prasad resigns following controversies over gene therapy approvals, sparking criticism from Trump allies and patient groups ...